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Abstract 
 
Background 
Pharmacovigilance is the “science and activities relating to 
the detection, assessment, understanding and prevention of 
adverse effects or any other drug related problems”. Nepal 
joined the international pharmacovigilance programme as a 
full member in 2007. KIST Medical College, Lalitpur, Nepal 
joined the national programme as a regional centre from 
mid-July 2008. Currently, the pattern and scope of adverse 
drug reactions (ADRs) in Nepal remains unexplored. 
Aims 
To observe and analyse the pattern of ADRs at KIST Medical 
College, Lalitpur, Nepal. 
Method   
A retrospective analysis of all ADRs reported to the centre 
from mid July 2008 to July 2011 was performed. Data was 
analysed for ADR severity, causality, and preventability. 
Results 
A  total  of  113  ADR  reports  were  obtained  from  various 
clinical  departments.  The  maximum  number  of  reactions 
was due to antimicrobials, followed by anti-hypertensives 
and NSAIDs.  
Conclusion 
Antimicrobials were the commonest group of drugs causing 
ADRs and the most commonly seen ADR was maculopapular 
rash followed by diarrhea and vomiting. 
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What this study adds: 
•  The study examines ADRs reported over a three-
year period to a regional pharmacovigilance centre 
in Nepal 
•  The  possible  reasons  for  under-reporting  are 
discussed in this study. 
•  The study highlights the need for further research 
to identify causes for under-reporting 
 
Background 
Pharmacovigilance is the “science and activities relating to 
the detection, assessment, understanding and prevention of 
adverse  effects  or  any  other  drug  related  problems”.
1 
Pharmacovigilance plays an important role in rational use of 
medicines  by  providing  information  about  adverse  drug 
reactions  (ADRs)  in  the  general  population.
1  In  the  year 
2004, pharmacovigilance activities were initiated in Nepal 
which  became  a  full  member  of  the  international 
pharmacovigilance programme in 2007.
2 The Department of 
Drug  Administration  (DDA),  the  national  drug  regulatory 
authority  of  Nepal  acts  as  the  national  centre  for  ADR 
monitoring. KIST Medical College joined the programme as a 
regional centre from July 2008. 
 
Pharmacovigilance in Nepal: In Nepal, hospitals report ADRs 
to  the  regional  pharmacovigilance  centres  from  where 
reports are sent to the national pharmacovigilance centre. 
From  there  reports  are  sent  to  the  Uppsala  Monitoring 
Centre (UMC), Sweden, the international centre. At present, 
there are six regional pharmacovigilance centres located in 
teaching hospitals which report ADRs to the national centre 
via a web-based system called ‘Vigiflow’.  
 
In  Nepal,  there  is  no  mandatory  law  necessitating  drug 
manufacturers  to  submit  safety  data  from  the  Nepalese 
population prior to approval of the medicines. Hence, it is 
very  necessary  to  monitor  side  effects  of  the  medicines 
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available in the market as the information collected during 
the  pre-marketing  phase  is  inevitably  incomplete  with 
regard to possible ADRs.
3 Nepal is a developing country and 
has several medicine use problems. The majority of drugs 
used are manufactured in foreign countries and the safety 
profile  of  the  excipients,  diluents,  binders,  stabilisers  and 
other additives used to prepare medicines are not known. 
The genetic make-up of the Nepalese population is varied 
which might be a predisposing factor for ADRs.
4,5 The annual 
consumption  of  drugs  in  Nepal  is  estimated  to  be  worth 
over  3719.3  million  Nepalese  rupees  (US$53.12  million), 
with  an  estimated  28.5%  increase  in  consumption  every 
year.
6 
 
Method 
The  study  was  a  retrospective  analysis  of  ADRs  reported 
from  mid  July  2008  to  July  2011  to  the  regional 
pharmacovigilance  centre  at  the  KIST  Medical  College, 
Lalitpur, Nepal.  The medical college has an attached 300-
bed tertiary care hospital. 
 
ADR  reporting  forms  designed  to  report  reactions  to  the 
centre  were  available  in  all  wards  and  outpatient 
departments  (OPDs)  of  the  hospital.  Patient  and  drug 
details, date of starting and stopping the drug and date of 
reporting the ADR, brief description of reaction, and name 
and  signature  of  the  reporter  are  requested  in  the  ADR 
reporting  form.  The  information  regarding  reaction  and 
other basic  information  was completed and submitted to 
the  Pharmacovigilance  centre  for  analysis  of  the  case. 
Technical  assessments  for  causality,  severity  and 
preventability were performed. Naranjo algorithm was used 
to  categorise  ADRs  for  causality  as  possibly,  probably  or 
definitely for each drug.
7 Modified Hartwig and Siegel scale 
was  used  to  categorise  the  reported  ADRs  into  different 
levels as mild, moderate or severe.
8 Shumock and Thornton 
scale was used to determine the preventability of an ADR.
9  
 
Table 1: Common classes of drugs causing ADRs  
Drug Class  Number (Percentage) 
Antimicrobials  51 (45.13%) 
Antihypertensives  15 (31.27%) 
NSAIDs  13 (11.5%) 
Proton pump inhibitors  5 (4.42%) 
Corticosteroids  5 (4.42%) 
Thiazides  5 (4.42%) 
Anti-epileptics  5 (4.42%) 
Bronchodilators  3 (2.65%) 
 
 
 
Results  
The total number of adverse drug reaction reports over the 
audit period was 113. More than half the ADRs reported 
occurred  in  female  patients  (55.35%),  and  nearly  half 
(44.24%) the patients were in the age group of 21-40 years. 
Sixty-eight (60.17%) ADRs were reported by the Department 
of  Medicine  followed  by  the  Paediatrics  Department  [18 
(15.92%)].  Antimicrobials  were  the  class  of  drugs  causing 
the highest number of ADRs followed by antihypertensive 
drugs (Table 1).   
Most  common  drugs  causing  ADRs  were  azithromycin, 
amlodipine,  ciprofloxacin,  diclofenac,  fluconazole, 
ceftriaxone, amoxicillin, carbamazepine and thiazides.  
Causality assessment as per Naranjo’s scale showed that 60 
(67.80%) ADRs were probably caused by the drug and 40 
(45.50%)  ADRs  were  possibly  caused  by  the  drug.  The 
severity  assessment  showed  that  12  (10.61%)  ADRs  were 
mild level (1), 54 (47.70%) ADRs were moderate level (2) 34 
(30.08%) ADRs were moderate level (3) 8 (7.07%) reactions 
were  moderate  level  4(a)  and  5  (4.42%)  ADRs  were 
moderate level 4(b).   
 
Preventability assessment showed that only 13 (11.50%) of 
the  reported  ADRs  were  definitely  preventable.  Thirty 
(26.54%) ADRs were probably preventable and 70 (61.94%) 
were not preventable.  
Table 2 shows the different types of adverse drug reactions 
reported along with their frequency.  
Table 2:  Types of adverse drug reactions reported 
Reaction  Number (frequency) 
Maculopapular rash  25 (22.12%) 
Vomiting  19 (16.81%) 
Diarrhea  13 (11.50%) 
Rash  12 (10.61%) 
Drug fever  4 (3.53%) 
Pedal oedema  4 (3.53%) 
Headache  2 (1.76%) 
Vertigo  2 (1.76%) 
Elevation of liver 
enzymes 
2 (1.76%) 
Bradycardia  2 (1.76%) 
Tremor  2 (1.76%) 
Dry cough  2 (1.76%) 
Giddiness and dizziness  2 (1.76%) 
Swelling of limbs  2 (1.76%) 
Rigors and chills  2 (1.76%) 
 
Discussion 
There was a higher prevalence of ADRs in females with a 
female:  male  ratio  of  1:  0.74,  which  is  comparable  with  Australasian Medical Journal [AMJ 2012, 5, 5, 268-271] 
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other studies; one study showed a female: male ratio of 1: 
0.87
10 while another study showed a ratio of 1.8:1.
11  
 
Females  have  been  identified  as  being  at  higher  risk  for 
developing  ADRs.  The  underlying  reasons  may  be  various 
physiological  reasons  like  menstruation,  menarche, 
pregnancy,  lactation  and  menopause  and  a  stronger 
immune response in women. In a study from a South Indian 
hospital, the majority of patients experiencing ADRs were in 
the age group 21-40 years.
10 Another study in a tertiary care 
centre  in  South  India  showed  the  age  group  20-39  years 
suffered from more ADRs.
12 
 
The top 10 drugs responsible for causing ADRs reported to 
the national pharmacovigilance centre from centres all over 
the  country  were  carbamazepine,  phenytoin,  amoxicillin, 
ciprofloxacin, diclofenac, isoniazid, ibuprofen, paracetamol, 
tramadol and cotrimoxazole.
13  
 
The skin is the largest organ of the body and most ADRs are 
seen  in  the  skin.
14  Maculopapular  rashes  were  the  most 
commonly  reported  type  of  ADR.  This  result  is  in 
concordance with the studies by Sushma et al.
10 and Puavilai 
and colleagues.
15 In our study, azithromycin was the most 
common  drug  causing  ADRs  followed  by  ibuprofen  and 
amlodipine.  In  a  study  done  by  Fiszensin-Albala  and  co-
workers from France, the main drug group responsible for 
ADRs  was  antibiotics.
16  However,  another  study  done  by 
Noel  and  co-workers  showed  anti-epileptics  as  the  major 
causative drugs for causing the ADRs.
17  
 
The current system of reporting ADRs remains in its infancy. 
Future plans for the development of this  system include: 
strengthening  the  reporting  system  by  training  the  new 
faculties and medical officers in each department about the 
pharmacovigilance programe in our hospital; following up 
all clinical departments weekly for improving the quality of 
reporting;  providing  feedback  to  the  clinicians  about  the 
progress  of  their  reported  reactions  to  facilitate  an 
improvement  in  the  problem  of  under-reporting. 
Medication errors and error reporting are still controversial 
issues  and  will  have  to  be  discussed  before  an  error 
reporting programme can be initiated.    
 
Limitations 
Our study did not evaluate the association of ethnic group, 
caste and religion, and polypharmacy with ADRs. Also, some 
of the reports for ayurvedic and complementary medicines 
could  not  be  assessed  due  to  the  lack  of  information 
regarding  its  composition,  dose  and  frequency.  Lack  of 
awareness  and  information  about  medication  errors  and 
also non-availability of medication error reporting systems 
which is an important part of pharmacovigilance is a major 
limitation.  
 
Conclusion 
Antimicrobials were the commonest group of drugs causing 
ADRs  and  the  most  commonly  observed  ADR  was 
maculopapular  rash  followed  by  vomiting  and  diarrhoea. 
Efforts  are  underway  to  encourage  clinicians,  nurses  and 
other  allied  healthcare  workers  to  report  all  ADRs  even 
suspected ones, with the aim of improving medicine use.  
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